RBC: Sciele still at sector perform

Sciele Pharma, Inc. was maintained at a sector perform, above average risk rating by RBC Capital Markets analyst Ken Trbovich as the company reported $74.8 million in sales compared to RBC's estimate of $75.0 and Thomson consensus of $71.9 million. Better-than-expected gross margins of 86.3% actual compared to RBC's 85.5% estimate offset higher-than-expected research and development expenses. Shares of the Atlanta-based pharmaceutical company were up $1.18, or 5.76%, at $21.67. (Nasdaq: SCRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.